While innovation in interventional cardiology has historically come from small companies, industry consolidation and a flattening of technology has, in recent years, given the edge to large suppliers, which now all but dominate the field. Drug-eluting stents, which require huge resource expenditures, seem to epitomize this shift of interventional cardiology to a big-company game. But in at least one highly promising area--bifurcated lesions--small companies continue to have the edge in developing a device to effectively treat this significant unmet clinical need. Encouraging for these smaller companies is the fact that the critical technology hurdle in treating bifurcations is primarily mechanical, not biological, enabling new approaches that can potentially complement, not compete against, drug-coated stents.
by Stephen Levin
Although it's only been a couple of years since the spectacular first clinical results of drug-eluting stents (DES) were reported...
Join thousands of industry professionals who rely on In Vivo for daily insights
Already a subscriber?
An interactive look at pharma, medtech and diagnostics deals made during May 2025. Data courtesy of Biomedtracker.
Flagship Pioneering senior partner Raj Panjabi discusses shifting health care from reactive treatment to AI-powered prediction and prevention of disease before symptoms emerge.
Namrata Saroj, chief business officer of Ocular Therapeutix, is highly respected in the retina community for her contributions to drug development. She talked to In Vivo about her journey in ophthalmology, leadership philosophy and the importance of authenticity in a close-knit specialty.
